Marshall Wace LLP Reduces Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Marshall Wace LLP trimmed its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 631,628 shares of the biopharmaceutical company's stock after selling 631,657 shares during the quarter. Marshall Wace LLP owned 1.11% of Agios Pharmaceuticals worth $20,755,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the fourth quarter valued at about $33,000. Wingate Wealth Advisors Inc. purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at about $53,000. Sterling Capital Management LLC grew its position in Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the last quarter. KBC Group NV increased its stake in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the period. Finally, AlphaQuest LLC lifted its position in Agios Pharmaceuticals by 106.2% in the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after purchasing an additional 2,338 shares during the last quarter.

Insider Activity

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded up $0.42 on Friday, reaching $29.68. The stock had a trading volume of 145,302 shares, compared to its average volume of 703,184. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 2.62 and a beta of 0.83. The company has a 50-day simple moving average of $30.38 and a 200-day simple moving average of $38.33.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AGIO has been the subject of several analyst reports. StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.